https://www.investing.com/news/company-news/telix-pharmaceuticals-plans-nasdaq-listing-93CH-3446532
InvestingPro Insights
Telix Pharmaceuticals Limited (ASX: TLX), as it prepares for its Nasdaq debut, presents a compelling profile according to recent data from InvestingPro. With a market capitalization of approximately $20.12 billion USD and a P/E ratio of 11.56, the company appears to be valued favorably in relation to its earnings. Adjusted for the last twelve months as of Q4 2023, the P/E ratio is slightly lower at 11.28, indicating a stable earnings perspective relative to its share price.
InvestingPro Tips suggest that Telix Pharmaceuticals is expected to see net income growth this year, which could be a positive signal for potential investors looking at the long-term viability of the company. Moreover, the company is trading at a high EBITDA valuation multiple, which may reflect market optimism regarding its future profitability and growth potential.
Financially, the company has demonstrated solid revenue growth, with a 12.72% increase in the last twelve months as of Q4 2023. The quarterly revenue growth for Q4 2023 was even more impressive at 32.25%. These figures underscore Telix's strong financial performance and potential for continued expansion in the biopharmaceutical sector.
- Forums
- ASX - By Stock
- TLX
- Ann: Telix Reports Q1 2024 Financial Performance
Ann: Telix Reports Q1 2024 Financial Performance, page-24
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.84 |
Change
-0.090(0.45%) |
Mkt cap ! $6.721B |
Open | High | Low | Value | Volume |
$20.10 | $20.54 | $19.79 | $39.55M | 1.959M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 1173 | $19.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.85 | 797 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 1738 | 19.860 |
18 | 2955 | 19.850 |
14 | 1945 | 19.840 |
5 | 682 | 19.830 |
8 | 1546 | 19.820 |
Price($) | Vol. | No. |
---|---|---|
19.870 | 4462 | 17 |
19.880 | 1596 | 11 |
19.890 | 1785 | 7 |
19.900 | 618 | 5 |
19.910 | 1612 | 6 |
Last trade - 15.44pm 15/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online